<?xml version="1.0" encoding="UTF-8"?>
<xml>
  <records>
    <record>
      <source-app name="Horizon">Horizon</source-app>
      <rec-number>1</rec-number>
      <foreign-keys>
        <key app="Horizon" db-id="fdi:010064892">1</key>
      </foreign-keys>
      <ref-type name="Journal Article">17</ref-type>
      <work-type>ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES</work-type>
      <contributors>
        <authors>
          <author>
            <style face="normal" font="default" size="100%">Suaysod, R.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Ngo-Giang-Huong, Nicole</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Salvadori, Nicolas</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Cressey, T. R.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Kanjanavanit, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Techakunakorn, P.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Krikajornkitti, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Srirojana, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Laomanit, L.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Chalermpantmetagul, S.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Lallemant, Marc</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Le Coeur, S.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">McIntosh, K.</style>
          </author>
          <author>
            <style face="normal" font="default" size="100%">Traisathit, P.</style>
          </author>
          <author>
            <style face="bold" font="default" size="100%">Jourdain, Gonzague</style>
          </author>
        </authors>
      </contributors>
      <titles>
        <title>Treatment failure in HIV-infected children on second-line protease inhibitor-based antiretroviral therapy</title>
        <secondary-title>Clinical Infectious Diseases</secondary-title>
      </titles>
      <pages>95-101</pages>
      <keywords>
        <keyword>antiretroviral therapy failure</keyword>
        <keyword>HIV-infected children</keyword>
        <keyword>protease inhibitor</keyword>
        <keyword>second-line ART</keyword>
        <keyword>genotypic resistance</keyword>
        <keyword>THAILANDE</keyword>
      </keywords>
      <dates>
        <year>2015</year>
      </dates>
      <call-num>fdi:010064892</call-num>
      <language>ENG</language>
      <periodical>
        <full-title>Clinical Infectious Diseases</full-title>
      </periodical>
      <isbn>1058-4838</isbn>
      <accession-num>ISI:000359323500016</accession-num>
      <number>1</number>
      <electronic-resource-num>10.1093/cid/civ271</electronic-resource-num>
      <urls>
        <related-urls>
          <url>https://www.documentation.ird.fr/hor/fdi:010064892</url>
        </related-urls>
        <pdf-urls>
          <url>https://www.documentation.ird.fr/intranet/publi/2015/09/010064892.pdf</url>
        </pdf-urls>
      </urls>
      <volume>61</volume>
      <remote-database-provider>Horizon (IRD)</remote-database-provider>
      <abstract>Background. Human immunodeficiency virus (HIV)-infected children failing second-line antiretroviral therapy (ART) have no access to third-line antiretroviral drugs in many resource-limited settings. It is important to identify risk factors for second-line regimen failure. Methods. HIV-infected children initiating protease inhibitor (PI)-containing second-line ART within the Program for HIV Prevention and Treatment observational cohort study in Thailand between 2002 and 2010 were included. Treatment failure was defined as confirmed HIV type 1 RNA load &gt;400 copies/mL after at least 6 months on second-line regimen or death. Adherence was assessed by drug plasma levels and patient self-report. Cox proportional hazards regression analyses were used to identify risk factors for failure. Results. A total of 111 children started a PI-based second-line regimen, including 59 girls (53%). Median first-line ART duration was 1.9 years (interquartile range [IQR], 1.4-3.3 years), and median age at second-line initiation was 10.7 years (IQR, 6.3-13.4 years). Fifty-four children (49%) experienced virologic failure, and 2 (2%) died. The risk of treatment failure 24 months after second-line initiation was 41%. In multivariate analyses, failure was independently associated with exposure to first-line ART for &gt;2 years (adjusted hazard ratio [aHR], 1.8; P = .03), age &gt; 13 years (aHR, 2.9; P &lt; .001), body mass index-for-age z score &lt; -2 standard deviations at second-line initiation (aHR, 2.8; P = .03), and undetectable drug levels within 6 months following second-line initiation (aHR, 4.5; P &lt; .001). Conclusions. Children with longer exposure to first-line ART, entry to adolescence, underweight, and/or undetectable drug levels were at higher risk of failing second-line ART and thus should be closely monitored.</abstract>
      <custom6>052 ; 050</custom6>
      <custom1>UR174</custom1>
      <custom7>Thaïlande</custom7>
    </record>
  </records>
</xml>
